SIWA Therapeutics: A New Supernova to Discover!

Press Releases
Meet SIWA Therapeutics, the startup challenging aging, cancer and degenerative diseases. Senescent cells (cells that have stopped dividing due to damage) are causally connected with aging and aging-related diseases, including cancer. “While they don’t divide like cancer cells, senescent cells are highly active metabolically,” explains SIWA co-founder and CEO, Lewis Gruber. “They can poison the tumor micro-environment — inducing, progressing and metastasizing cancer in the cells around them.”  Therefore, Gruber and SIWA developed a monoclonal antibody, SIWA 318H, that is sensitive to a marker appearing on both senescent cells and cancer cells, ultimately binding to the cell, destroying it and removing the debris. “In our first in-vivo study, we successfully removed the senescent cells,” explains SIWA co-founder and Chief Strategy Officer, Misty Gruber. “In the second in-vivo study, we reduced…
Read More